{"id":"arxiv:1906.07511","kind":"article","title":"ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease","authors":["Florent Letronne","Geoffroy Laumet","Anne-Marie Ayral","Julien Chapuis","Florie Demiautte","Mathias Laga","Michel Vandenberghe","Nicolas Malmanche","Florence Leroux","Fanny Eysert","Yoann Sottejeau","Linda Chami","Amandine Flaig","Charlotte Bauer","Pierre Dourlen","Marie Lesaffre","Charlotte Delay","Ludovic Huot","Julie Dumont","Elisabeth Werkmeister","Franck Lafont","Tiago Mendes","Franck Hansmannel","Bart Dermaut","Benoit Deprez"],"author_count":41,"year":2019,"published":"2019-06-18","venue":"EBioMedicine, Elsevier, 2016, 9, pp.278-292","cited_by":58,"doi":"10.1016/j.ebiom.2016.06.002","arxiv_id":"1906.07511","nct_id":null,"source_url":"https://arxiv.org/abs/1906.07511","archive_url":"https://space-kitty.com/papers/arxiv:1906.07511","updated":"2019-06-18","pmid":null,"pmcid":null,"openalex_id":"W2417224687","pdf_url":"https://arxiv.org/pdf/1906.07511","abstract":"Although several ADAMs (A disintegrin-like and metalloproteases) have been shown to contribute to the amy-loid precursor protein (APP) metabolism, the full spectrum of metalloproteases involved in this metabolism remains to be established. Transcriptomic analyses centred on metalloprotease genes unraveled a 50% decrease in ADAM30 expression that inversely correlates with amyloid load in Alzheimer's disease brains. Accordingly, in vitro down-or up-regulation of ADAM30 expression triggered an increase/decrease in A$β$ peptides levels whereas expression of a biologically inactive ADAM30 (ADAM30 mut) did not affect A$β$ secretion. Proteomics/cell-based experiments showed that ADAM30-dependent regulation of APP metabolism required both cathepsin D (CTSD) activation and APP sorting to lysosomes. Accordingly, in Alzheimer-like transgenic mice, neuronal ADAM30 over-expression lowered A$β$42 secretion in neuron primary cultures, soluble A$β$42 and amyloid plaque load levels in the brain and concomitantly enhanced CTSD activity and finally rescued long term potentiation.","abstract_license":"CC0-1.0 (arXiv descriptive metadata)","license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["q-bio.NC","q-bio.TO"],"details":null,"provenance":"arxiv","attribution":"Abstract: arXiv descriptive metadata (CC0). Thank you to arXiv for use of its open access interoperability. This service was not reviewed or approved by, nor does it necessarily express or reflect the policies or opinions of, arXiv.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}